ORMP
Oramed Pharmaceuticals Inc
4.70$
-1.2%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | |
| – | – | -100.0% | – | – | – | +6,309.7% | -98.5% | +3.3% | -3.2% | +0.0% | -100.0% | – | |
| – | – | – | – | – | – | – | -330.8% | – | – | – | – | – | |
| – | +79.0% | -31.2% | +22.3% | +55.5% | -34.8% | +51.0% | -53.1% | +11.5% | +72.4% | -19.8% | -100.0% | – | |
| – | -18.8% | -15.5% | -5.0% | -50.0% | +151.9% | +8.1% | -36.9% | -12.4% | +189.2% | -43.9% | +33.9% | – | |
| – | +32.2% | -22.5% | +5.8% | -1.5% | +15.4% | +26.6% | -44.8% | -3.7% | +135.5% | -35.1% | -24.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +46.6% | -51.1% | -55.9% | +5,808.0% | +0.0% | -83.4% | -100.0% | – | – | – | – | – | |
| – | – | -88.5% | +606.5% | -270.8% | – | – | – | +352.6% | -83.5% | +404.6% | +105.5% | – | |
| – | – | – | – | -30.7% | -63.3% | +40.4% | -121.6% | – | -101.9% | – | +110.5% | – | |
| – | – | -88.5% | +499.7% | -313.0% | – | – | – | +264.2% | -79.3% | +282.8% | +104.0% | – | |
| – | – | – | +411.1% | -265.5% | – | – | – | +351.9% | -109.5% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.